Inhalation Sciences receives IRS order worth 1.9 million SEK with US pharma company

Inhalation Sciences AB (ISAB) has received an order worth 1.9 MSEK (178,000 Euros) for an Inhalation Research Service (IRS) project with a mid-sized US pharma company. The project will use ISAB’s leading in vitro dissolution and absorption module DissolvIt^® to test the dissolution profiles of a new inhaled drug.

The project will test the dissolution profiles of a new drug with several formulations, both with and without excipients. It will also test if the drug’s dissolution properties are maintained when scaling up production.

ISAB’s in vitro dissolution technology - DissolvIt^® - can discriminate and generate comprehensive data across several testing micronization methods, formulations and APIs.

ISAB CEO Manoush Masarrat: “It has been a great year for our IRS research services! We know that there is a growing number of mid-size pharmaceutical companies developing groundbreaking respiratory drugs like this one who have a real need for high-quality service providers with an extensive range of skills, expertise, and instruments particularly in the discovery to preclinical stage. This once again confirms our outlined strategy of focusing on research services and we are delighted to be working with our new partner on this exciting project.”

READ MORE

Explore DissolvIt’s capabilities here.

Read ISAB’s publications on DissolvIt^® here.

Explore Inhalation Research Services here